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estimate the ratio of incremental expected cost of ramipril
therapy to the incremental life year gained (LYG). All
costs were discounted at 3% per year. RESULTS: Dis-
counted cost for within-trial CE analysis was $2600 for
ramipril compared to $1554 for placebo (incremental
cost, $1046). With a 2% absolute risk reduction in
within-trial cardiac mortality, the incremental cost/LYG
was $11,622. Cost/LYG under the persistent beneﬁt was
$4509. For extended beneﬁt of therapy, cost/LYG was
$4014. Sensitivity analysis ranged from cost/LYG of
$3143 to $12,689. CONCLUSIONS: Ramipril is CE in
preventing CV events in high-risk patients across multi-
ple therapy beneﬁt scenarios.
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OBJECTIVES: To estimate hospital costs and charges
attributable to the development of acute renal insufﬁ-
ciency (ARI) and acute renal failure (ARF) after coronary
artery bypass grafting (CABG). METHODS: A retro-
spective analysis of patients undergoing CABG at Uni-
versity of Pittsburgh Medical Center from June 1998
through May 2002 was conducted. Patients were
matched with respect to severity of illness by APACHE
III scores. A Wilcoxon signed-rank test was used to assess
differences in costs and charges. RESULTS: There were
3741 total patients that resulted in 644 matched pairs.
The mean and median hospital charges among cases were
approximately $221,864 and $158,312 respectively. The
mean and median hospital charges among controls were
approximately $110,868 and $91,738 respectively. Dis-
tribution of the hospital charges were positively skewed
(Shapiro-Wilk test, 0 < 0.001). The difference in median
hospital charges was $66,500 (Wilcoxon signed-rank test,
p < 0.01). The mean and median hospital costs among
cases were $44,180 and $28,901 respectively. The mean
and median hospital costs among controls were $22,471
and $18,038 respectively. The difference in median hos-
pital costs was $10,863 (Wilcoxon signed-rank test, p <
0.01). The mean and median ICU costs among cases were
$35,566 and $21,183 respectively. The mean and median
ICU costs among controls were $17,634 and $13,655
respectively. The difference in median ICU costs was
$7528 (Wilcoxon signed-rank test, p < 0.01). CONCLU-
SIONS: Although patients were matched using APACHE
III scores, a severity of illness scoring system, patients
with ARI/ARF after CABG had signiﬁcantly higher hos-
pital and ICU costs and charges than patients without
ARI/ARF. These differences can be attributed to the devel-
opment of renal complications after CABG.
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Sudden death is one of the two main causes of mortality
in congestive heart failure. Implanted cardioverter deﬁb-
rillator (ICD) is an expensive but highly effective treat-
ment in preventing sudden death. The gain of primary
prophylactic ICD in preventing sudden death in heart
failure has not been clearly established. OBJECTIVE:
Compare the cost-effectiveness of prophylactic ICD with
conventional treatment for preventing sudden death.
METHODS: A lifetime decision model was built. The
perspective is societal. The target population is U.S. HF
patients, aged 60, with NYHA functional Class II and III.
Estimates of cost, utility and probabilities are taken from
literature, clinical experts, CMS fee schedule payment,
and the Bureau of Labor Statistics. In all cases, we assume
that ICD is effective in preventing all sudden death, and
the ICD would be reimplanted at ninth year. In our base
case, we assume that total annual mortality rate is 20%,
of which sudden death accounts for 40%; the utility of
ICD is 10% less during the 1st year after implantation,
and reverts back to pre-implantation level in the 2nd year.
We did a one-way sensitivity analyses on all model para-
meters. RESULTS: the lifetime cost is $117,095 for
patients with prophylactic ICD and $24,709 for patients
with conventional treatment in 2002; the QALYs gained
were 2.9088 and 1.9045 respectively. The CE ratio was
$91,990 per QALY saved. We failed to show that ICD is
cost-effectiveness under any plausible scenario if we use
$50,000 per quality-adjusted-life-year saved as the cut-off
point. CE ratio is sensitive to the utility at the second 
and subsequent years after ICD implantation, and the
proportion of sudden death in all HF-related deaths.
CONCLUSIONS: Using conventional cost effectiveness
benchmarks of $50,000 per life year saved, it is unlikely
that ICD would be cost-effectiveness in preventing sudden
death compared to conventional treatment for heart
failure patients. Future research should focus on patient
utility with and without ICD.
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OBJECTIVES: Previous studies have used Markov
models to predict future CHF hospitalizations based on
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a patient’s multiple prior admissions. Our objective is to
develop a model that predicts future admissions based on
left ventricular ejection fraction (LVEF) and the occur-
rence of a CHF admission in the preceding quarter.
Another objective is to use this model to examine, in a
managed care setting, the cost-beneﬁt of the following
CHF management strategies: ACE inhibitor therapy, beta
blocker therapy, CHF disease management, and inten-
sive case management. METHODS: We constructed a
Markov model to project the medical and non-medical
costs for a cohort of CHF patients in a commercially
insured population. The model deﬁnes four disease states
based on LVEF status (normal vs. low) and a prior admis-
sion (yes vs. no) in the preceding quarter. The probabil-
ity of a future admission depends on the patient’s disease
state as well as age and gender. Plan-speciﬁc CHF admis-
sion probabilities were calibrated using claims analyses.
Each intervention is assumed to change health service 
utilization patterns and improve survival. Cost-beneﬁt 
is expressed as net savings in medical and non-medical
costs. RESULTS: For a population of 100,000 commer-
cially insured individuals, CHF case rate and medical
costs are predicted to increase steadily over the next 5
years. Intensive case management appears to be the most
cost-beneﬁcial intervention, with an estimated per
member per month (PMPM) net savings of $0.11 in the
ﬁrst year. Beta blocker therapy is expected to save $0.08
in the ﬁrst year, while ACE inhibitors and CHF disease
management show net positive savings starting year 2. All
interventions remain cost-beneﬁcial when non-medical
savings are eliminated from the analyses. CONCLU-
SIONS: The four CHF management strategies modeled
are not only effective in improving clinical outcomes; they
are also predicted to be cost-beneﬁcial in a managed care
setting.
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OBJECTIVES: Coronary artery disease (CAD) is the
second most important disease resulting in mortality 
in Hong Kong. The most severe manifestation is acute
myocardial infarction (AMI). Both treatment and cardiac
rehabilitation for AMI are costly. Cost of management of
AMI is an important baseline information for better plan-
ning under scarce allocation of medical resources. The
present study aims to evaluate the cost of management of
explicit Q-wave AMI in a local public hospital in Hong
Kong. METHODS: A retrospective study was performed
on patients admitted to the United Christian Hospital.
The study cohort consisted of one hundred patients
admitted to Coronary Care Unit who were aged 18 year
old or above with a diagnosis of Q-wave AMI from 1
January 2000 to 31 December 2000. Cost items studied
included hospital stay, outpatient clinic visits, diagnostic
tests, medications, and percutaneous coronary interven-
tions. RESULTS: Ninety-eight case notes (2 case note
were incomplete) were evaluated. The average annual
medical cost per patient for AMI management in this 
population was USD $8990 (1 US $ = 7.8HK$). The total
annual cost per patient per year increased with the com-
plexity of the disease—from USD $7320 for non-fatal MI
without procedure, USD $10,963 for non-fatal MI with
angiogram, to USD $12,030 for non-fatal MI with pro-
cedure. Based on the local epidemiological data, the
prevalence rate of CAD is 2.2% and assuming 3% of
patients may experience AMI with medical care, the esti-
mated total cost of AMI management in Hong Kong was
USD $45 million per year, or 0.5% of the 2000–01
healthcare expenditure. CONCLUSIONS: The present
study provides information of the cost of AMI manage-
ment in Hong Kong. It conﬁrms that AMI management
is a signiﬁcant burden to the healthcare budget. Public
awareness on CAD and implementation of appropriate
health measures should be reinforced.
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OBJECTIVE: To determine the impact of acute rheumatic
fever (ARF) and chronic rheumatic heart disease (CRHD)
on hospital expenditure in the United States. METHODS:
This study analyzed data from the Healthcare Cost and
Utilization Project (2000) funded by the Agency for
Healthcare Research and Quality. Hospitalizations due 
to ARF and CRHD were identiﬁed using ICD-9 codes
390–398 as principal diagnoses. RESULTS: In 2000,
there were approximately 1226 and 44,659 hospitaliza-
tions due to ARF and CRHD, respectively. Females
accounted for about 58% of all hospitalizations due to
ARF, and 63% due to CRHD. The elderly aged 65 years
and older accounted for 74% of the hospitalizations due
to CRHD, followed by adults aged 35–64 years (24%).
The two most common comorbid conditions associated
with CRHD were atrial ﬁbrillation (49%) and hyperten-
sion (34%). The two most common procedures per-
formed during CRHD hospitalizations were
extracorporeal circulation for open heart surgery (10%)
and diagnostic ultrasound of the heart (7%). The mean
(and median) length of hospital stay for ARF and CRHD
was 7.5 (5) and 7.9 (6) days, respectively. Average charge
per hospital stay was about $29,500 for ARF and
